Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32212
Title: Phenytoin poisoning.
Authors: Craig S. 
Institution: (Craig) Monash Medical Centre, Clayton, Vic., Australia (Craig) Monash Medical Centre, Locked Bag 29, Clayton, Vic. 3169, Australia
Issue Date: 18-Oct-2012
Copyright year: 2005
Publisher: Humana Press (999 Riverview Drive, Suite 208, Totowa NJ 07512-1165, United States)
Place of publication: United States
Publication information: Neurocritical Care. 3 (2) (pp 161-170), 2005. Date of Publication: October 2005.
Abstract: Phenytoin toxicity may result from intentional overdose, dosage adjustments, drug interactions, or alterations in physiology. Intoxication manifests predominantly as nausea, central nervous system dysfunction (particularly confusion, nystagmus, and ataxia), with depressed conscious state, coma, and seizures occurring in more severe cases. Cardiac complications such as arrhythmias and hypotension are rare in cases of phenytoin ingestion, but they may be seen in parenteral administration of phenytoin or fosphenytoin. Deaths are unlikely after phenytoin intoxication alone. A greatly increased half-life in overdose due to zero-order pharmacokinetics can result in a prolonged duration of symptoms and thus prolonged hospitalization with its attendant complications. The mainstay of therapy for a patient with phenytoin intoxication is supportive care. Treatment includes attention to vital functions, management of nausea and vomiting, and prevention of injuries due to confusion and ataxia. There is no antidote, and there is no evidence that any method of gastrointestinal decontamination or enhanced elimination improves outcome. Activated charcoal should be considered if the patient presents early; however, the role of multiple-dose activated charcoal is controversial. Experimental studies have proven increased clearance rates, but this effect has not been translated into clinical benefit. There is no evidence that any invasive method of enhanced elimination (such as plasmapheresis, hemodialysis, or hemoperfusion) provides any benefit. This article provides an overview of phenytoin pharmacokinetics and the clinical manifestations of toxicity, followed by a detailed review of the various treatment modalities. Copyright © 2005 Humana Press Inc. All rights of any nature whatsoever are reserved.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1385/NCC:3:2:161
PubMed URL: 16174888 [http://www.ncbi.nlm.nih.gov/pubmed/?term=16174888]
ISSN: 1541-6933
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/32212
Type: Review
Type of Clinical Study or Trial: Review article (e.g. literature review, narrative review)
Appears in Collections:Articles

Show full item record

Page view(s)

26
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.